SCHEMBL901182

SCHEMBL901182

Clc1[c]ccc(Oc2ccc(Cl)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.47
MAOB P27338 2/20 0.47
LTA4H P09960 6/20 0.43
AR P10275 1/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21630305 0.85 TEAD4 (0.44) ARALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL21630390 0.85 LTA4H (0.41) MAOAMAOBLTA4HALDH1A1SMN1; SMN2
SCHEMBL21630310 0.85 MAPT (0.44) MAOAMAOBLTA4HALDH1A1MAPT
SCHEMBL21630308 0.85 SOS1 (0.38) PDE4APDE4BPDE4CPDE4DSCN9A
SCHEMBL4156310 0.84 LTA4H (0.48) MAOAMAOBLTA4HALDH1A1SMN1; SMN2
SCHEMBL28575004 0.81 S1PR2 (0.34) LTA4HSMN1; SMN2LMNASCN9A
SCHEMBL21630309 0.81 MAOA (0.44) MAOAMAOBLTA4HARALDH1A1
SCHEMBL921457 0.81 MAOA (0.44) MAOAMAOBLTA4HARALDH1A1
SCHEMBL21632255 0.80 HAO1 (0.33)
SCHEMBL21630319 0.80 PARP15 (0.42) MAOBARALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113717035-B Recycling method of difenoconazole waste intermediate 江苏禾本生化有限公司 2024-03-26 CN claimed
CN-114437049-A Preparation method for synthesizing difenoconazole by three-step method 江西农业大学 2022-05-06 CN claimed
CN-113717035-A Recycling method of difenoconazole waste intermediate 江苏禾本生化有限公司 2021-11-30 CN claimed
EP-1465869-B1 MODULATORS OF LXR EXELIXIS PATENT CO LLC (US) 2013-05-15 EP claimed
CN-102432566-A 2- (4-phenoxyphenyl) oxirane and preparation method and application thereof UNIV HUNAN 2012-05-02 CN claimed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US claimed
US-6989351-B2 Metabolic inhibitors against brassinosteroids RIKEN (JP) 2006-01-24 US claimed
EP-1465869-A4 MODULATORS OF LXR X CEPTOR THERAPEUTICS INC (US) 2005-12-28 EP claimed
JP-2005536450-A 2005-12-02 JP claimed
US-20040259735-A1 Metabolic inhibitors against brassinosteroids RIKEN (JP) 2004-12-23 US claimed
EP-1465869-A1 MODULATORS OF LXR X-Ceptor Therapeutics, Inc. (US) 2004-10-13 EP claimed
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS, INC. 2003-09-25 US claimed
WO-2003059884-A1 MODULATORS OF LXR X-CEPTOR THERAPEUTICS, INC. (US) 2003-07-24 WO claimed
EP-1304038-A1 METABOLIC INHIBITORS AGAINST BRASSINOSTEROIDS RIKEN (JP) 2003-04-23 EP claimed
EP-0572085-A1 Fungicidal compositions ISAGRO S.r.l. (IT) 1993-12-01 EP claimed
CN-113717035-B Recycling method of difenoconazole waste intermediate 江苏禾本生化有限公司 2024-03-26 CN disclosed
CN-113717035-B Recycling method of difenoconazole waste intermediate 江苏禾本生化有限公司 2024-03-26 CN disclosed
EP-0529974-A1 Fungicidal 2-aryl-2-cyano-2-(aryloxyalkyl)ethyl-1,2,4-triazoles ROHM AND HAAS COMPANY (US) 1993-03-03 EP disclosed
US-5162329-A Fungicides BASF AKTIENGESELLSCHAFT (DE) 1992-11-10 US disclosed
EP-0461487-A2 Beta picoline derivatives and plant protecting agents containing them BASF Aktiengesellschaft (DE) 1991-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors NR1H2, NR1H3, NCOA1 MAOA 1629/4885MAOB 1238/4885LTA4H 1706/4885
US-20040259735-A1 Metabolic inhibitors against brassinosteroids DBI, HSD17B4, ABHD5 MAOA 3498/4885MAOB 2370/4885LTA4H 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.